Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Tackling and investigating the South-Kivu mpox outbreak

Project description

Addressing the monkeypox virus outbreak in South Kivu

The new monkeypox virus (MPXV, clade Ib) lineage outbreak in South Kivu, Republic of the Congo is concerning due to its high human-to-human transmission rates through sexual contact. Prompt intervention can prevent international spread. The EU-funded MBOTE-SK project aims to secure emergency funding to tackle the outbreak in South Kivu. It will adopt an approach that includes enhancing case finding and epidemiological surveillance for clade Ib MPXV, implementing real-time genomic monitoring of the virus, improving clinical care through detailed studies, and engaging key populations, such as sex workers, to address community spread, vaccine hesitancy, and stigma. Insights will support the Ministry of Health’s vaccination campaign with the Modified Vaccinia Ankara vaccine, including assessment of its effectiveness.

Objective

With the Mpox Biology, Outcome, Transmission, and Epidemiology in South Kivu (MBOTE-SK) project, we seek emergency funding to address one of the most alarming mpox outbreaks currently unfolding: the ongoing emergence of a new lineage of monkeypox virus (MPXV, clade Ib) in South Kivu, Democratic Republic of the Congo (DRC). This outbreak is particularly concerning due to its extensive human-to-human transmission through sexual contact in a densely populated region characterized by a large sex industry and significant cross-border movement. Without swift intervention, there is a high risk of the outbreak spreading internationally, penetrating sexual networks worldwide.
In this project, we will leverage our extensive experience with mpox outbreaks in the DRC and our current presence in South Kivu to tackle this outbreak through a combined approach of research and response. To achieve this, we will build on local and national expertise and strengthen the DRC's research institutions, and align with the international response.
This project has four foundational pillars, each designed to simultaneously strengthen the response and comprehensively describe clade Ib MPXV, including its clinical presentation, mode of transmission, at-risk populations, and virological evolution. Pillar 1 strengthens active case finding and epidemiological surveillance to map and monitor the spread of clade Ib MPXV. Pillar 2 supports real-time genomic surveillance to track the genetic evolution of the strain. Pillar 3 enhances clinical care through an in-depth clinical characterization study. Pillar 4 engages key populations (including sex workers) to study community spread, vaccine hesitancy and stigma. These four pillars eventually feed into Pillar 5, by informing on how to best target the Ministry of Health’s planned vaccination campaign (with the Modified Vaccinia Ankara vaccine) and documenting its impact and real-world effectiveness (using the established platforms of Pillars 1-4).

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-GH-EDCTP3-2024-Mpox

See all projects funded under this call

Coordinator

INSTITUUT VOOR TROPISCHE GENEESKUNDE
Net EU contribution
€ 299 142,50
Address
NATIONALESTRAAT 155
2000 ANTWERPEN
Belgium
Region
Vlaams Gewest Prov. Antwerpen Arr. Antwerpen
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 843 947,50

Participants (5)

Partners (2)